Brief: Xvivo Perfusion Q4 EBIT Loss At SEK 14.3 Million
Jan 28 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q4 TOTAL NET SALES (INCL. DURABLE GOODS) IN QUARTER
AMOUNTED TO
SEK 60.3 (62.4) MILLION
* Q4 OPERATING INCOME (EBIT) AMOUNTED TO SEK -14.3 (1.6)
MILLION
Source text for Eikon: ID:nMFN6nvmq7
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength